Breeze Holdings Acquisition Corp. is a clinical-stage biopharmaceutical company based in Taipei, Taiwan. The firm concentrates its efforts on developing medical diagnostics for cancer prevention and creating exosome-based therapeutics, both of which aim to revolutionize treatment options for diseases with significant unmet medical needs.
Subscribe to see YD Bio Limited’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
YD Bio Limited is a biotech company headquartered in Taipei, Taiwan. It is publicly listed (YDES) with a market capitalisation of $476.7M. Xcout tracks 8 named people at YD Bio Limited, including Ethan Shen (CEO & Chairman).
2 more named people on record for YD Bio Limited, with roles, board committees and tenure — see the full roster →
A few of YD Bio Limited's closest competitors — see the full list of competitors and alternatives →
Established in 1998 and headquartered in Taipei, Taiwan, PhytoHealth Corporation specializes in the research, development, production, and commercialization of a diverse portfolio including pharmaceutical products, cosmetic lines, specific over-the-counter medications (Class B), and nutritional supplements. Their prominent offerings feature the PG2 Lyophilized injection, specifically designed to alleviate cancer-related fatigue. The company also markets EnerCharge, available both as a formula to boost physical vigor and maintain mental alertness, and as an energy beverage. Another notable product is ReyeasCleanse health food capsules. Furthermore, PhytoHealth extends its expertise to precision medical devices, specialized diagnostic software, and licensing services for computer-aided diagnostic systems.
NovelStem International Corp. concentrates its efforts on pioneering and introducing diagnostic solutions for cancer treatment, specifically with the goal of mitigating chemotherapy resistance. The company, which commenced operations in 1993, was previously recognized as Hollywood Media Corp. before adopting its current name in September of 2018. Its corporate headquarters are situated in Boca Raton, Florida.
Niki BioSolutions is a biopharmaceutical company that resulted from the merger of Aptorum Group and DiamiR Biosciences. The company focuses on developing and commercializing a diverse portfolio of therapeutic and diagnostic assets. Its work spans from treatments for diseases with unmet medical needs, particularly in oncology and infectious diseases, to the development of innovative, blood-based diagnostic tests for brain health and other conditions.
Asep Medical Holdings Inc., operating primarily through its subsidiary ASEP Medical Inc., is dedicated to advancing both a rapid diagnostic system for Sepsis and a range of peptide-based therapeutic treatments applicable across various medical conditions. The company, initially incorporated in 2020 under the name Trenchant Life Sciences Investment Corp., later rebranded to its present title, Asep Medical Holdings Inc. Its corporate base of operations is located in Vancouver, Canada.
Mammoth Biosciences is a biotechnology company based in Brisbane, California developing diagnostic tests using CRISPR-Cas12a and CRISPR-based therapies using its proprietary ultra-small CRISPR systems. Several CRISPR-Cas systems identified through the company's metagenomics-based protein discovery platform, including members of the Casφ and Cas14 families of CRISPR-associated enzymes, have demonstrated potential for therapeutic genome editing in in vivo settings.
AXIM Biotechnologies, Inc. specializes in the creation and distribution of advanced diagnostic solutions for healthcare, focusing on critical areas such as SARS-CoV-2 (COVID-19), ocular health, and cancer treatment. The company is currently developing rapid diagnostic assays that quantify functional neutralizing antibodies, which are essential for preventing the SARS-CoV-2 virus from attaching to human cells. Additionally, it offers serological diagnostic tests designed to detect neutralizing antibodies, thereby assessing the body's adaptive immune response to the virus, and is developing tests to identify inflammation biomarkers for the effective management of COVID-19 patients. For eye health, AXIM is pioneering quick, quantitative tear tests to measure Matrix metalloproteinase-9, an inflammatory marker associated with dry eye disease. In its oncology pipeline, the firm is advancing SBI-183, an anti-metastatic compound engineered to inhibit tumor cell growth and block the spread of cancer, as well as SPX-1009, another anti-metastatic therapy aimed at determining the levels of quiescin sulfhydryl oxidase I. Established in 2010, the company was formerly known as Axim International Inc. before officially changing its name to AXIM Biotechnologies, Inc. in July 2014, and it is headquartered in San Diego, California.
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Post the link and the card appears automatically — each network fetches the image itself.